Literature DB >> 26237169

Re-invigorating rather than re-inventing the wheel: augmenting the impact of salvage autologous stem cell transplantation for multiple myeloma in the era of novel agents.

G Cook1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26237169     DOI： 10.1038/bmt.2015.175

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  11 in total

1.  Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).

Authors:  Murielle Roussel; Philippe Moreau; Anne Huynh; Jean-Yves Mary; Clotaire Danho; Denis Caillot; Cyrille Hulin; Christophe Fruchart; Gérald Marit; Brigitte Pégourié; Pascal Lenain; Carla Araujo; Brigitte Kolb; Edouard Randriamalala; Bruno Royer; Anne-Marie Stoppa; Mammoun Dib; Véronique Dorvaux; Laurent Garderet; Claire Mathiot; Hervé Avet-Loiseau; Jean-Luc Harousseau; Michel Attal
Journal:  Blood       Date:  2009-11-02       Impact factor: 22.113

2.  Bortezomib, lenalidomide and dexamethasone (VRD) combination as salvage therapy in refractory angioimmunoblastic T cell lymphoma.

Authors:  Driss Chaoui; Sonia Bouallegue; Nina Arakelyan; Philippe Genet; Ahmad Aljijakli; Laurent Sutton
Journal:  Br J Haematol       Date:  2014-03       Impact factor: 6.998

3.  Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors.

Authors:  Paola Neri; Li Ren; Kathy Gratton; Erin Stebner; Jordan Johnson; Alexander Klimowicz; Peter Duggan; Pierfrancesco Tassone; Adnan Mansoor; Douglas A Stewart; Sagar Lonial; Lawrence H Boise; Nizar J Bahlis
Journal:  Blood       Date:  2011-09-13       Impact factor: 22.113

4.  A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study.

Authors:  Sagar Lonial; Jonathan Kaufman; Mourad Tighiouart; Ajay Nooka; Amelia A Langston; Leonard T Heffner; Claire Torre; Stephanie McMillan; Heather Renfroe; R Donald Harvey; Mary J Lechowicz; H Jean Khoury; Christopher R Flowers; Edmund K Waller
Journal:  Clin Cancer Res       Date:  2010-08-25       Impact factor: 12.531

5.  Re-transplantation after bortezomib-based therapy.

Authors:  Curly Morris; Gordon Cook; Matthew Streetly; Paul Kettle; Mary Drake; Michael Quinn; Jim Cavet; Jane Tighe; Majit Kazmi; John Ashcroft; Mark Cook; John Snowden; Ade Olujohungbe; Scott Marshall; Jane Conn; Heather Oakervee; Rakesh Popat; Jamie Cavenagh
Journal:  Br J Haematol       Date:  2011-01-31       Impact factor: 6.998

6.  High-dose intravenous melphalan for plasma-cell leukaemia and myeloma.

Authors:  T J McElwain; R L Powles
Journal:  Lancet       Date:  1983-10-08       Impact factor: 79.321

Review 7.  Fifty years of melphalan use in hematopoietic stem cell transplantation.

Authors:  Ulas D Bayraktar; Qaiser Bashir; Muzaffar Qazilbash; Richard E Champlin; Stefan O Ciurea
Journal:  Biol Blood Marrow Transplant       Date:  2012-08-24       Impact factor: 5.742

8.  Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  Laurent Garderet; Simona Iacobelli; Philippe Moreau; Mamoun Dib; Ingrid Lafon; Dietger Niederwieser; Tamas Masszi; Jean Fontan; Mauricette Michallet; Alois Gratwohl; Giuseppe Milone; Chantal Doyen; Brigitte Pegourie; Roman Hajek; Philippe Casassus; Brigitte Kolb; Carine Chaleteix; Bernd Hertenstein; Francesco Onida; Heinz Ludwig; Nicolas Ketterer; Christian Koenecke; Marleen van Os; Mohamad Mohty; Andrew Cakana; Norbert Claude Gorin; Theo de Witte; Jean Luc Harousseau; Curly Morris; Gösta Gahrton
Journal:  J Clin Oncol       Date:  2012-05-14       Impact factor: 44.544

9.  Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial.

Authors:  P Gimsing; Ø Hjertner; N Abildgaard; N F Andersen; T G Dahl; H Gregersen; T W Klausen; U-H Mellqvist; O Linder; R Lindås; N Tøffner Clausen; S Lenhoff
Journal:  Bone Marrow Transplant       Date:  2015-06-29       Impact factor: 5.483

10.  The impact of novel therapeutic agents before and after frontline autologous stem cell transplantation in patients with multiple myeloma.

Authors:  Chang-Ki Min; Sung-Eun Lee; Seung-Ah Yahng; Byung-Sik Cho; Ki-Seong Eom; Yoo-Jin Kim; Hee-Je Kim; Seok Lee; Seok-Goo Cho; Dong-Wook Kim; Jong-Wook Lee; Woo-Sung Min; Chong-Won Park
Journal:  Blood Res       Date:  2013-09-25
View more
  1 in total

1.  The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial.

Authors:  Alina Striha; A John Ashcroft; Anna Hockaday; David A Cairns; Karen Boardman; Gwen Jacques; Cathy Williams; John A Snowden; Mamta Garg; Jamie Cavenagh; Kwee Yong; Mark T Drayson; Roger Owen; Mark Cook; Gordon Cook
Journal:  Trials       Date:  2018-03-07       Impact factor: 2.279
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.